
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Pharmacokinetic/pharmacodynamic parameters of teicoplanin for predicting clinical outcome of glycopeptide-susceptible Enterococcus faecium bacteraemia - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4A6278AF24AC305A627000FB3E20C.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="jacamr">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368495/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="JAC-Antimicrobial Resistance">
<meta name="citation_title" content="Pharmacokinetic/pharmacodynamic parameters of teicoplanin for predicting clinical outcome of glycopeptide-susceptible Enterococcus faecium bacteraemia">
<meta name="citation_author" content="Ryo Yamaguchi">
<meta name="citation_author_institution" content="Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan">
<meta name="citation_author" content="Takehito Yamamoto">
<meta name="citation_author_institution" content="Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan">
<meta name="citation_author" content="Sohei Harada">
<meta name="citation_author_institution" content="Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan">
<meta name="citation_author" content="Mayu Shibuya">
<meta name="citation_author_institution" content="Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan">
<meta name="citation_author" content="Miyuki Mizoguchi">
<meta name="citation_author_institution" content="Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan">
<meta name="citation_author" content="Yoshimi Higurashi">
<meta name="citation_author_institution" content="Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan">
<meta name="citation_author" content="Miho Echizenya">
<meta name="citation_author_institution" content="Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan">
<meta name="citation_author" content="Takeya Tsutsumi">
<meta name="citation_author_institution" content="Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan">
<meta name="citation_author_institution" content="Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan">
<meta name="citation_author" content="Tappei Takada">
<meta name="citation_author_institution" content="Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan">
<meta name="citation_publication_date" content="2025 Aug 21">
<meta name="citation_volume" content="7">
<meta name="citation_issue" content="4">
<meta name="citation_firstpage" content="dlaf151">
<meta name="citation_doi" content="10.1093/jacamr/dlaf151">
<meta name="citation_pmid" content="40851898">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368495/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368495/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368495/pdf/dlaf151.pdf">
<meta name="description" content="The objective of this study was to determine the pharmacokinetic/pharmacodynamic parameters of teicoplanin associated with optimal outcomes in glycopeptide-susceptible Enterococcus faecium (GSEF) bacteraemia. We conducted a retrospective review of ...">
<meta name="og:title" content="Pharmacokinetic/pharmacodynamic parameters of teicoplanin for predicting clinical outcome of glycopeptide-susceptible Enterococcus faecium bacteraemia">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The objective of this study was to determine the pharmacokinetic/pharmacodynamic parameters of teicoplanin associated with optimal outcomes in glycopeptide-susceptible Enterococcus faecium (GSEF) bacteraemia. We conducted a retrospective review of ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368495/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12368495">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1093/jacamr/dlaf151"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/dlaf151.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12368495%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12368495/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12368495/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368495/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-jacamr.png" alt="JAC-Antimicrobial Resistance logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to JAC-Antimicrobial Resistance" title="Link to JAC-Antimicrobial Resistance" shape="default" href="https://academic.oup.com/jacamr" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">JAC Antimicrob Resist</button></div>. 2025 Aug 21;7(4):dlaf151. doi: <a href="https://doi.org/10.1093/jacamr/dlaf151" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1093/jacamr/dlaf151</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22JAC%20Antimicrob%20Resist%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22JAC%20Antimicrob%20Resist%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22JAC%20Antimicrob%20Resist%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22JAC%20Antimicrob%20Resist%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Pharmacokinetic/pharmacodynamic parameters of teicoplanin for predicting clinical outcome of glycopeptide-susceptible <em>Enterococcus faecium</em> bacteraemia</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yamaguchi%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Ryo Yamaguchi</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Ryo Yamaguchi</span></h3>
<div class="p">
<sup>1</sup>
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yamaguchi%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Ryo Yamaguchi</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yamamoto%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Takehito Yamamoto</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Takehito Yamamoto</span></h3>
<div class="p">
<sup>2</sup>
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yamamoto%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Takehito Yamamoto</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Harada%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Sohei Harada</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Sohei Harada</span></h3>
<div class="p">
<sup>3</sup>
Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Harada%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sohei Harada</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shibuya%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Mayu Shibuya</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Mayu Shibuya</span></h3>
<div class="p">
<sup>4</sup>
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shibuya%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mayu Shibuya</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mizoguchi%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Miyuki Mizoguchi</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Miyuki Mizoguchi</span></h3>
<div class="p">
<sup>5</sup>
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mizoguchi%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Miyuki Mizoguchi</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Higurashi%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Yoshimi Higurashi</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Yoshimi Higurashi</span></h3>
<div class="p">
<sup>6</sup>
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Higurashi%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yoshimi Higurashi</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Echizenya%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Miho Echizenya</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Miho Echizenya</span></h3>
<div class="p">
<sup>7</sup>
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Echizenya%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Miho Echizenya</span></a>
</div>
</div>
<sup>7</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tsutsumi%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Takeya Tsutsumi</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Takeya Tsutsumi</span></h3>
<div class="p">
<sup>8</sup>
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan</div>
<div class="p">
<sup>9</sup>
Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tsutsumi%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Takeya Tsutsumi</span></a>
</div>
</div>
<sup>8,</sup><sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Takada%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Tappei Takada</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Tappei Takada</span></h3>
<div class="p">
<sup>10</sup>
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Takada%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tappei Takada</span></a>
</div>
</div>
<sup>10</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>1</sup>
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan</div>
<div id="aff2">
<sup>2</sup>
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan</div>
<div id="aff3">
<sup>3</sup>
Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan</div>
<div id="aff4">
<sup>4</sup>
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan</div>
<div id="aff5">
<sup>5</sup>
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan</div>
<div id="aff6">
<sup>6</sup>
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan</div>
<div id="aff7">
<sup>7</sup>
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan</div>
<div id="aff8">
<sup>8</sup>
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan</div>
<div id="aff9">
<sup>9</sup>
Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan</div>
<div id="aff10">
<sup>10</sup>
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan</div>
<div class="author-notes p"><div class="fn" id="dlaf151-cor1">
<sup>✉</sup><p class="display-inline">Corresponding author. E-mail: <span>ryamaguchi-tky@g.ecc.u-tokyo.ac.jp</span></p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 May 27; Accepted 2025 Aug 5; Collection date 2025 Aug.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.</div>
<p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12368495  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40851898/" class="usa-link">40851898</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="s1"><h3 class="pmc_sec_title">Objectives</h3>
<p>The objective of this study was to determine the pharmacokinetic/pharmacodynamic parameters of teicoplanin associated with optimal outcomes in glycopeptide-susceptible <em>Enterococcus faecium</em> (GSEF) bacteraemia.</p></section><section id="s2"><h3 class="pmc_sec_title">Patients and methods</h3>
<p>We conducted a retrospective review of GSEF bacteraemia cases treated with teicoplanin between 1 April 2009 and 30 May 2023. Total area under the concentration–time curve over 24 h (AUC<sub>24</sub>) was calculated using a Bayesian approach. The free AUC<sub>24</sub> (fAUC<sub>24</sub>) was estimated based on patient serum albumin levels. MICs were determined using the gradient diffusion method (Etest), and the fAUC<sub>24</sub>/MIC<sub>Etest</sub> ratio was calculated. The primary outcome was treatment failure, defined as a composite of (i) 30-day all-cause mortality and (ii) microbiological failure, defined as persistent bacteraemia (a positive follow-up blood culture obtained &gt;72 h after initiation of appropriate therapy). Classification and regression tree analysis (CART) was employed to identify the optimal teicoplanin fAUC<sub>24</sub>/MIC<sub>Etest</sub> value associated with treatment failure.</p></section><section id="s3"><h3 class="pmc_sec_title">Results</h3>
<p>A total of 76 patients were included. Treatment failure occurred in 18 patients (23.7%). A CART-derived teicoplanin fAUC<sub>24</sub>/MIC<sub>Etest</sub> ≥ 462 was significantly associated with reduced treatment failure (<em>P</em> = 0.002). Multivariable regression analysis revealed that achievement of an fAUC<sub>24</sub>/MIC<sub>Etest</sub> ≥ 462 was an independent predictor significantly associated with reduced treatment failure (OR, 0.099; 95% CI, 0.005–0.562; <em>P</em> = 0.032).</p></section><section id="s4"><h3 class="pmc_sec_title">Conclusions</h3>
<p>An fAUC<sub>24</sub>/MIC<sub>Etest</sub> ≥ 462 was associated with a reduction in treatment failure in GSEF bacteraemia. Further studies are necessary to establish optimal pharmacokinetic/pharmacodynamic targets for GSEF bacteraemia.</p></section></section><section id="dlaf151-s1"><h2 class="pmc_sec_title">Introduction</h2>
<p>Enterococci are commensal bacteria residing in the intestinal tract, yet they can cause serious infections.<sup><a href="#dlaf151-B1" class="usa-link" aria-describedby="dlaf151-B1">1</a></sup> Mortality rates associated with enterococcal bacteraemia have been reported to range between 20% and 40%.<sup><a href="#dlaf151-B2" class="usa-link" aria-describedby="dlaf151-B2">2–4</a></sup> The European Antimicrobial Resistance Surveillance System (EARSS) database has documented a continuous increase in <em>Enterococcus faecium</em> bacteraemia cases, with vancomycin-resistant <em>E. faecium</em> (VRE) emerging as a major global concern.<sup><a href="#dlaf151-B5" class="usa-link" aria-describedby="dlaf151-B5">5</a>,<a href="#dlaf151-B6" class="usa-link" aria-describedby="dlaf151-B6">6</a></sup> While the prevalence of VRE remains relatively low in Japan,<sup><a href="#dlaf151-B7" class="usa-link" aria-describedby="dlaf151-B7">7</a></sup> this regional heterogeneity underscores the critical need to optimize treatment strategies for glycopeptide-susceptible <em>E. faecium</em> (GSEF) infections to preserve the efficacy of available agents such as teicoplanin.</p>
<p>Teicoplanin, a glycopeptide antibiotic, is widely used in Europe and the Asia-Pacific region, including Japan, due to its superior <em>in vitro</em> activity against enterococci compared to vancomycin and its longer half-life, which allows once-daily dosing.<sup><a href="#dlaf151-B8" class="usa-link" aria-describedby="dlaf151-B8">8</a></sup> Our previous research evaluated the effectiveness and safety of teicoplanin versus vancomycin in the treatment of GSEF bacteraemia.<sup><a href="#dlaf151-B9" class="usa-link" aria-describedby="dlaf151-B9">9</a></sup> The results demonstrated that teicoplanin was non-inferior to vancomycin for GSEF bacteraemia treatment, with a significantly lower incidence of acute kidney injury (AKI) associated with teicoplanin. Based on these findings, teicoplanin may be considered a viable alternative to vancomycin in the treatment of GSEF bacteraemia. However, the relationship between the pharmacokinetic/pharmacodynamic (PK/PD) parameters of teicoplanin and its therapeutic effectiveness in GSEF bacteraemia has yet to be fully elucidated.</p>
<p>The PK/PD parameter most commonly associated with the clinical efficacy of teicoplanin against MRSA is the ratio of the AUC to the MIC, referred to as AUC/MIC.<sup><a href="#dlaf151-B10" class="usa-link" aria-describedby="dlaf151-B10">10</a>,<a href="#dlaf151-B11" class="usa-link" aria-describedby="dlaf151-B11">11</a></sup> The target AUC/MIC ratio for teicoplanin against MRSA is approximately 600–900, and achieving this target is known to improve therapeutic outcomes.<sup><a href="#dlaf151-B12" class="usa-link" aria-describedby="dlaf151-B12">12</a>,<a href="#dlaf151-B13" class="usa-link" aria-describedby="dlaf151-B13">13</a></sup> Furthermore, teicoplanin is a highly protein-bound drug (approximately 90%), and it is the unbound (free) fraction that exerts antimicrobial activity. In critically ill patients, conditions such as hypoalbuminaemia can alter protein binding, potentially affecting the free drug concentration and therapeutic efficacy. Therefore, evaluating the free AUC/MIC (fAUC/MIC) ratio is considered more pharmacologically relevant than using the total concentration. However, the relationship between the fAUC/MIC ratio and the therapeutic effectiveness of teicoplanin in GSEF bacteraemia, along with the optimal target values, remains unclear. Consequently, the current dosing regimen for teicoplanin in GSEF bacteraemia is extrapolated from the regimen used for MRSA. Given that different bacterial strains may have distinct PK/PD targets even when treated with the same antibiotic, the optimal PK/PD parameters of teicoplanin for GSEF bacteraemia differ from those for MRSA, necessitating further investigation to determine a more appropriate fAUC/MIC ratio.<sup><a href="#dlaf151-B14" class="usa-link" aria-describedby="dlaf151-B14">14</a></sup></p>
<p>This study aimed to elucidate the relationship between the fAUC/MIC ratio of teicoplanin and its therapeutic effectiveness for GSEF bacteraemia and to identify the optimal target fAUC/MIC ratio.</p></section><section id="dlaf151-s2"><h2 class="pmc_sec_title">Patients and methods</h2>
<section id="dlaf151-s2.1"><h3 class="pmc_sec_title">Study design and setting</h3>
<p>We conducted a retrospective, single-centre, observational cohort study at The University of Tokyo Hospital between 1 April 2009 and 30 May 2023. The University of Tokyo’s ethics review board approved the study protocol (approval no. 2023138NI) and waived the requirement for written informed consent. The study was conducted in accordance with the ethical standards of the 1964 Declaration of Helsinki and its subsequent amendments. Patients with at least one GSEF-positive blood culture who received teicoplanin during the study period were deemed eligible. The exclusion criteria were as follows: lack of storage of microbiological samples, lack of teicoplanin trough concentration (<em>C</em><sub>min</sub>), age under 18 years, renal replacement therapy or initiation of teicoplanin treatment more than 72 h after infection. GSEF bacteraemia was defined as one or more blood cultures positive for <em>E. faecium</em> resistant to ampicillin, and susceptible to teicoplanin and vancomycin, accompanied by signs or symptoms of infection consistent with suspected infection sites, as established in previous studies.<sup><a href="#dlaf151-B9" class="usa-link" aria-describedby="dlaf151-B9">9</a>,<a href="#dlaf151-B15" class="usa-link" aria-describedby="dlaf151-B15">15</a>,<a href="#dlaf151-B16" class="usa-link" aria-describedby="dlaf151-B16">16</a></sup> Polymicrobial infections were included in the analysis. For patients with a history of multiple treatments for GSEF bacteraemia, only the first treatment was considered.</p></section><section id="dlaf151-s2.2"><h3 class="pmc_sec_title">Data collection</h3>
<p>We collected demographic and clinical data from patient medical records, including age, sex, height, weight, infection type (community- or hospital-acquired), ICU stay, comorbidities, Charlson Comorbidity Index (CCI), Pitt bacteraemia score and laboratory data such as serum creatinine (sCr), serum albumin (ALB), haemoglobin, total bilirubin (T-Bil), blood urea nitrogen (BUN), C-reactive protein, white blood cell count, absolute neutrophil count (ANC) and platelet count. These data were recorded on or immediately prior to the day the first GSEF-positive blood culture was obtained. Community-acquired infections were defined as those when the first GSEF-positive blood culture was obtained ≤48 h after hospitalization, while hospital-acquired infections were defined as those when the first positive culture occurred &gt;48 h after admission. The estimated glomerular filtration rate (eGFR) was calculated using the formula recommended by the Japanese Society of Nephrology.<sup><a href="#dlaf151-B17" class="usa-link" aria-describedby="dlaf151-B17">17</a></sup> Neutropenia was defined as an ANC &lt; 500 cells/mm<sup>3</sup>.<sup><a href="#dlaf151-B18" class="usa-link" aria-describedby="dlaf151-B18">18</a></sup> Immunocompromised patients were those who had received cancer chemotherapy, radiation therapy or immunosuppressive agents, including calcineurin inhibitors or corticosteroids, within the 30 days preceding the first GSEF-positive blood culture.<sup><a href="#dlaf151-B19" class="usa-link" aria-describedby="dlaf151-B19">19</a></sup> The sources of bacteraemia were determined based on microbiological and clinical criteria.<sup><a href="#dlaf151-B16" class="usa-link" aria-describedby="dlaf151-B16">16</a></sup> Therapy duration was defined as the period of teicoplanin administration. Source control, such as endoscopic retrograde cholangiopancreatography, percutaneous transhepatic biliary drainage or central venous catheter removal, was defined as any incision, drainage, or debridement performed during teicoplanin therapy. Appropriate antimicrobial therapy was defined as the intravenous administration of antimicrobial agents to which all isolated pathogens were susceptible, within 24 h of obtaining the positive blood culture.<sup><a href="#dlaf151-B2" class="usa-link" aria-describedby="dlaf151-B2">2</a>,<a href="#dlaf151-B20" class="usa-link" aria-describedby="dlaf151-B20">20</a></sup> Co-administered antibiotics other than teicoplanin were reviewed to assess the appropriateness of antimicrobial therapy.</p></section><section id="dlaf151-s2.3"><h3 class="pmc_sec_title">Microbiological data</h3>
<p>Blood culture specimens were processed using the BACTEC FX system (Becton Dickinson Microbiology Systems, Sparks, MD, USA). Species identification of bacterial isolates recovered from blood cultures was performed using the MALDI Biotyper 1.0 (Bruker Daltonics, Bremen, Germany). Antimicrobial susceptibilities to ampicillin and teicoplanin were tested using the MicroScan WalkAway system (Beckman Coulter Japan, Tokyo, Japan) and interpreted according to the Clinical and Laboratory Standards Institute (M100-S26) breakpoints.<sup><a href="#dlaf151-B21" class="usa-link" aria-describedby="dlaf151-B21">21</a></sup> Polymicrobial bacteraemia was defined as cases where one or more microorganisms, in addition to <em>E. faecium</em>, were isolated from the same blood culture and were not classified as contaminants according to the CDC criteria.<sup><a href="#dlaf151-B16" class="usa-link" aria-describedby="dlaf151-B16">16</a></sup></p>
<p>For this study, teicoplanin MIC determinations were performed on archived isolates using a commercial automated broth microdilution method with the MicroScan WalkAway-96 Plus system (MIC<sub>WalkAway</sub>) (Beckman Coulter) and gradient diffusion method (MIC<sub>Etest</sub>) (Etest, bioMérieux) following the manufacturer’s instructions. Due to a change in the MIC measurement range during the study period, all isolates were remeasured using the MicroScan WalkAway-96 Plus system for consistency. The MIC<sub>WalkAway</sub> measurement range was 2, 4, 8, and 16 mg/L. The MIC<sub>Etest</sub> results were reviewed and confirmed independently by three clinical microbiologists who were blinded to the clinical outcomes of the patients from whom the isolates were obtained. In cases where disagreement occurred among all three operators, the MIC was retested and determined by the representative operator, taking the initial results into consideration.</p></section><section id="dlaf151-s2.4"><h3 class="pmc_sec_title">Teicoplanin dosing and PD data</h3>
<p>The primary PK/PD parameter for this study was the ratio of the estimated 24-h free-drug area under the curve to the MIC (fAUC<sub>24</sub>/MIC<sub>Etest</sub>). The estimation of fAUC<sub>24</sub> was based on total <em>C</em><sub>min</sub> measured during the maintenance phase of therapy (at least 3 days after treatment initiation). Our institutional dosing protocol recommends a loading dose of 8–10 mg/kg administered three times approximately every 12 h within the first 48 h for patients with normal renal function, followed by a maintenance dose of 6 mg/kg once daily from Day 3. This loading regimen is intended to rapidly achieve therapeutic concentrations, allowing <em>C</em><sub>min</sub> values measured during the maintenance phase to serve as a reliable surrogate for drug exposure. Teicoplanin doses were routinely proposed by a pharmacist using therapeutic drug monitoring (TDM) with a target <em>C</em><sub>min</sub> for teicoplanin set at 15–30 mg/L in line with guideline recommendations,<sup><a href="#dlaf151-B22" class="usa-link" aria-describedby="dlaf151-B22">22</a></sup> though actual dosing was determined at the discretion of the attending physician.</p>
<p>The estimation of fAUC<sub>24</sub> involved a multi-step process. First, the total drug AUC over a 24-h interval during the maintenance phase (AUC<sub>24</sub>) was calculated for each patient. This was based on individual total clearance (CL<sub>total</sub>) estimated from the observed <em>C</em><sub>min</sub> through Bayesian analysis. This analysis employed a previously developed population PK (PopPK) model for Japanese patients constructed by Nakayama et al.<sup><a href="#dlaf151-B23" class="usa-link" aria-describedby="dlaf151-B23">23</a></sup> This PopPK model was based on data from 120 Japanese adult inpatients with MRSA infections and incorporates creatinine clearance and body weight as covariates, making it applicable to our study population. The reported inter-individual variabilities (CV%) for the main parameters were 22.1% for clearance (CL) and 26.7% for volume of distribution (<em>V</em>), with a residual variability of 15.6%. Based on the estimated CL<sub>total</sub> for each patient, the AUC<sub>24</sub> was calculated as AUC<sub>24</sub> (mg·h/L) = daily maintenance dose (mg)/CL<sub>total</sub> (L/h).<sup><a href="#dlaf151-B13" class="usa-link" aria-describedby="dlaf151-B13">13</a>,<a href="#dlaf151-B24" class="usa-link" aria-describedby="dlaf151-B24">24</a></sup> Second, to account for the impact of hypoalbuminaemia, a patient-specific unbound fraction (fu) was estimated based on a validated model developed specifically for teicoplanin in a Japanese patient population by Yano et al.<sup><a href="#dlaf151-B25" class="usa-link" aria-describedby="dlaf151-B25">25</a></sup> The model predicts the fu using the patient’s ALB concentration with the following formula:</p>
<table class="disp-formula p" id="UM0001"><tr><td class="formula"><math id="mml-disp1" display="block" overflow="linebreak"><mrow><mi mathvariant="normal">fu</mi></mrow><mo>=</mo><mrow><mn>1</mn><mo>/</mo><mrow><mo stretchy="false">(</mo><mrow><mn>1</mn><mo>+</mo><mn>1</mn><mrow><mn>.78</mn><mo>×</mo><mi mathvariant="normal">ALB</mi></mrow></mrow><mo stretchy="false">)</mo></mrow></mrow></math></td></tr></table>
<p>where ALB is expressed in g/dL.</p>
<p>Finally, the free AUC<sub>24</sub> (fAUC<sub>24</sub>) was estimated by multiplying the total AUC<sub>24</sub> by fu. The resulting fAUC<sub>24</sub>/MIC<sub>Etest</sub> ratio was used for all subsequent PK/PD analyses.</p>
<p>PK parameters for each patient were determined using the TDM software, BMs-Pod (ver 8.06, <a href="https://bmspod.web.fc2.com/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://bmspod.web.fc2.com/</a>).<sup><a href="#dlaf151-B26" class="usa-link" aria-describedby="dlaf151-B26">26</a>,<a href="#dlaf151-B27" class="usa-link" aria-describedby="dlaf151-B27">27</a></sup></p></section><section id="dlaf151-s2.5"><h3 class="pmc_sec_title">Clinical outcomes</h3>
<p>The primary outcome, treatment failure, was defined as a composite of (i) 30-day all-cause mortality or (ii) microbiological failure, defined as persistent bacteraemia (a positive follow-up blood culture obtained &gt;72 h after initiation of appropriate therapy) in patients with at least one follow-up blood culture).<sup><a href="#dlaf151-B28" class="usa-link" aria-describedby="dlaf151-B28">28</a>,<a href="#dlaf151-B29" class="usa-link" aria-describedby="dlaf151-B29">29</a></sup> In patients without follow-up blood cultures, microbiological failure was not assessed, and treatment failure was determined solely based on 30-day all-cause mortality. Patients who did not meet the criteria for treatment failure were classified as having treatment success. Secondary outcomes included 90-day all-cause mortality (death within 90 days of the first positive GSEF blood culture), in-hospital mortality (death occurring during hospitalization), relapse (recurrence of GSEF bacteraemia after negative blood cultures following GSEF treatment) and readmission within 90 days of the first positive GSEF blood culture. Relapse was defined as recurrence of GSEF bacteraemia after documented microbiological clearance, confirmed by at least one negative follow-up blood culture. All clinical outcomes and PK parameter estimation (including AUC calculation) were conducted by an infectious disease pharmacist with access to treatment details and patient clinical courses. MIC measurements were performed independently by separate investigators and were integrated only after clinical outcome evaluation was completed. Safety outcomes included (i) incidence of AKI, diagnosed according to the KDIGO criteria (defined as 1.5× increase in sCr from baseline within 7 days or ≥0.3 mg/dL increase within 48 h of baseline following teicoplanin initiation)<sup><a href="#dlaf151-B30" class="usa-link" aria-describedby="dlaf151-B30">30</a></sup>; (ii) incidence of liver injury, defined as AST ≥ 90 U/L or ALT ≥ 126 U/L (≥3 times the upper limit during teicoplanin treatment)<sup><a href="#dlaf151-B31" class="usa-link" aria-describedby="dlaf151-B31">31</a></sup>; and (iii) other adverse events associated with teicoplanin use for GSEF bacteraemia.<sup><a href="#dlaf151-B15" class="usa-link" aria-describedby="dlaf151-B15">15</a></sup></p></section><section id="dlaf151-s2.6"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p>Continuous variables, expressed as medians with IQRs, were compared between the treatment success and treatment failure groups using the Mann–Whitney <em>U</em>-test. Categorical variables were compared between the two groups using the χ² test or Fisher’s exact test, as appropriate. To identify predictors of treatment failure, several steps were taken for the logistic regression analysis. First, classification and regression tree (CART) analysis was used to identify the optimal cut-off value for the fAUC<sub>24</sub>/MIC<sub>Etest</sub> associated with treatment failure, according to the previous vancomycin PK/PD study.<sup><a href="#dlaf151-B32" class="usa-link" aria-describedby="dlaf151-B32">32</a></sup> This created a dichotomous variable for the PK/PD parameter. Next, a multivariable logistic regression model was constructed to assess the independent effect of the fAUC<sub>24</sub>/MIC<sub>Etest</sub> on treatment failure. To ensure the model was clinically robust and to adjust for key prognostic factors, we included several covariates based on their established clinical importance in severe infections, as guided by previous literature.<sup><a href="#dlaf151-B33" class="usa-link" aria-describedby="dlaf151-B33">33–35</a></sup> Specifically, the CCI, immunosuppressed state and Pitt bacteraemia score were forced into the model as adjustment variables. Multicollinearity was assessed by calculating variance inflation factors (VIFs), with a VIF &gt; 10 indicating collinearity. In cases of collinearity, only one variable was included in the analysis. Model calibration was evaluated with the Hosmer–Lemeshow goodness-of-fit test, and discrimination was assessed using the area under the receiver operating characteristic curve. All analyses were performed using R version 4.3.1 (R Foundation for Statistical Computing, Vienna, Austria) and JMP Pro 18.0.1 (SAS Institute Inc., Cary, NC, USA). A two-sided <em>P</em> value &lt; 0.05 was considered statistically significant.</p></section></section><section id="dlaf151-s3"><h2 class="pmc_sec_title">Results</h2>
<section id="dlaf151-s3.1"><h3 class="pmc_sec_title">Characteristics of patients</h3>
<p>We identified 98 patients with <em>E. faecium</em> bacteraemia who received teicoplanin treatment, of whom 76 were included in the final analysis (Figure <a href="#dlaf151-F1" class="usa-link">1</a>). The baseline characteristics of the patients are summarized in Table <a href="#dlaf151-T1" class="usa-link">1</a>. The median ages were 61.5 years (IQR, 53.3–74.5) in the treatment success group and 56.5 years (IQR, 52.0–66.0) in the treatment failure group. Mechanical ventilation was used more frequently in the treatment failure group than in the treatment success group (27.8% versus 3.4%, <em>P</em> = 0.007). More than half of the patients in both groups were in an immunosuppressed state. Appropriate antimicrobial therapy and source control were implemented in over 80% of cases in both groups. Because the distribution of polymicrobial infections was balanced between the groups and appropriate therapy was achieved in more than 80% of cases in both groups, polymicrobial infection was not included as a variable in the multivariable regression analysis.</p>
<figure class="fig xbox font-sm" id="dlaf151-F1"><h4 class="obj_head">Figure 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12368495_dlaf151f1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6158/12368495/d7e52a064a7d/dlaf151f1.jpg" loading="lazy" height="461" width="710" alt="Figure 1."></a></p>
<div class="p text-right font-secondary"><a href="figure/dlaf151-F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flowchart of patient selection.</p></figcaption></figure><section class="tw xbox font-sm" id="dlaf151-T1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Baseline characteristics of patients</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">Characteristic</th>
<th align="center" rowspan="1" colspan="1">Overall (<em>n</em> = 76)</th>
<th align="center" rowspan="1" colspan="1">Treatment success (<em>n</em> = 58)</th>
<th align="center" rowspan="1" colspan="1">Treatment failure (<em>n</em> = 18)</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em> value</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Male sex</td>
<td rowspan="1" colspan="1">51 (67.1)</td>
<td rowspan="1" colspan="1">40 (69.0)</td>
<td rowspan="1" colspan="1">11 (61.1)</td>
<td rowspan="1" colspan="1">0.574</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Age (years)</td>
<td rowspan="1" colspan="1">61.0 (52.0–73.0)</td>
<td rowspan="1" colspan="1">61.5 (53.3–74.5)</td>
<td rowspan="1" colspan="1">56.5 (52.0–66.0)</td>
<td rowspan="1" colspan="1">0.416</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Height (cm)</td>
<td rowspan="1" colspan="1">163.1 (156.6–170.8)</td>
<td rowspan="1" colspan="1">162.8 (156.1–168.0)</td>
<td rowspan="1" colspan="1">164.8 (160.3–172.8)</td>
<td rowspan="1" colspan="1">0.356</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Weight (kg)</td>
<td rowspan="1" colspan="1">60.9 (53.4–67.0)</td>
<td rowspan="1" colspan="1">60.3 (48.5–66.7)</td>
<td rowspan="1" colspan="1">63.0 (56.8–71.6)</td>
<td rowspan="1" colspan="1">0.231</td>
</tr>
<tr>
<td rowspan="1" colspan="1">BMI</td>
<td rowspan="1" colspan="1">22.3 (19.7–25.3)</td>
<td rowspan="1" colspan="1">22.1 (19.7–25.1)</td>
<td rowspan="1" colspan="1">22.9 (20.3–26.5)</td>
<td rowspan="1" colspan="1">0.282</td>
</tr>
<tr>
<td rowspan="1" colspan="1">ICU stay</td>
<td rowspan="1" colspan="1">22 (28.9)</td>
<td rowspan="1" colspan="1">15 (25.9)</td>
<td rowspan="1" colspan="1">7 (38.9)</td>
<td rowspan="1" colspan="1">0.373</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Mechanical ventilation</td>
<td rowspan="1" colspan="1">7 (9.2)</td>
<td rowspan="1" colspan="1">2 (3.4)</td>
<td rowspan="1" colspan="1">5 (27.8)</td>
<td rowspan="1" colspan="1">0.007</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Hospital-acquired infection<sup><a href="#tblfn3" class="usa-link">a</a></sup>
</td>
<td rowspan="1" colspan="1">67 (88.2)</td>
<td rowspan="1" colspan="1">49 (84.5)</td>
<td rowspan="1" colspan="1">18 (100.0)</td>
<td rowspan="1" colspan="1">0.105</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Charlson Comorbidity Index</td>
<td rowspan="1" colspan="1">4.0 (3.0–6.0)</td>
<td rowspan="1" colspan="1">4.0 (3.0–6.0)</td>
<td rowspan="1" colspan="1">3.0 (2.3–5.0)</td>
<td rowspan="1" colspan="1">0.440</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Pitt bacteraemia score</td>
<td rowspan="1" colspan="1">1.0 (0.0–2.2)</td>
<td rowspan="1" colspan="1">1.0 (0–2.0)</td>
<td rowspan="1" colspan="1">1.5 (0–4.8)</td>
<td rowspan="1" colspan="1">0.313</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Hypertension</td>
<td rowspan="1" colspan="1">20 (26.3)</td>
<td rowspan="1" colspan="1">16 (27.6)</td>
<td rowspan="1" colspan="1">4 (22.2)</td>
<td rowspan="1" colspan="1">0.766</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Chemotherapy</td>
<td rowspan="1" colspan="1">14 (18.4)</td>
<td rowspan="1" colspan="1">12 (20.7)</td>
<td rowspan="1" colspan="1">2 (11.1)</td>
<td rowspan="1" colspan="1">0.497</td>
</tr>
<tr>
<td rowspan="1" colspan="1">COPD</td>
<td rowspan="1" colspan="1">4 (5.3)</td>
<td rowspan="1" colspan="1">4 (6.9)</td>
<td rowspan="1" colspan="1">0 (0)</td>
<td rowspan="1" colspan="1">0.567</td>
</tr>
<tr>
<td rowspan="1" colspan="1">WBC count (×10<sup>3</sup> cells/mm<sup>3</sup>)</td>
<td rowspan="1" colspan="1">7.6 (5.0–12.0)</td>
<td rowspan="1" colspan="1">8.1 (5.8–12.3)</td>
<td rowspan="1" colspan="1">5.5 (4.2–11.8)</td>
<td rowspan="1" colspan="1">0.224</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Neutrophil count (×10<sup>3</sup> cells/mm<sup>3</sup>)</td>
<td rowspan="1" colspan="1">6.0 (3.8–9.8)</td>
<td rowspan="1" colspan="1">7.1 (4.2–9.7)</td>
<td rowspan="1" colspan="1">3.9 (2.3–8.9)</td>
<td rowspan="1" colspan="1">0.079</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Neutropenia<sup><a href="#tblfn4" class="usa-link">b</a></sup>
</td>
<td rowspan="1" colspan="1">9 (11.8)</td>
<td rowspan="1" colspan="1">6 (10.3)</td>
<td rowspan="1" colspan="1">3 (16.7)</td>
<td rowspan="1" colspan="1">0.435</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Haemoglobin (g/dL)</td>
<td rowspan="1" colspan="1">8.8 (7.6–10.2)</td>
<td rowspan="1" colspan="1">9.4 (8.2–10.5)</td>
<td rowspan="1" colspan="1">8.2 (6.4–8.5)</td>
<td rowspan="1" colspan="1">0.002</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Platelet count (×10<sup>3</sup>/mm<sup>3</sup>)</td>
<td rowspan="1" colspan="1">10.6 (5.4–21.9)</td>
<td rowspan="1" colspan="1">12.5 (6.0–23.9)</td>
<td rowspan="1" colspan="1">6.3 (3.1–13.9)</td>
<td rowspan="1" colspan="1">0.036</td>
</tr>
<tr>
<td rowspan="1" colspan="1">BUN</td>
<td rowspan="1" colspan="1">21.0 (14.9–37.5)</td>
<td rowspan="1" colspan="1">17.7 (13.9–30.7)</td>
<td rowspan="1" colspan="1">34.7 (20.0–50.8)</td>
<td rowspan="1" colspan="1">0.010</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Serum creatinine (mg/dL)</td>
<td rowspan="1" colspan="1">1.0 (0.7–1.3)</td>
<td rowspan="1" colspan="1">0.9 (0.7–1.3)</td>
<td rowspan="1" colspan="1">1.1 (0.8–1.6)</td>
<td rowspan="1" colspan="1">0.149</td>
</tr>
<tr>
<td rowspan="1" colspan="1">eGFR (mL/min/1.73 m<sup>2</sup>)</td>
<td rowspan="1" colspan="1">58.5 (40.0–86.4)</td>
<td rowspan="1" colspan="1">62.4 (42.5–86.5)</td>
<td rowspan="1" colspan="1">47.8 (38.0–60.6)</td>
<td rowspan="1" colspan="1">0.160</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Serum albumin level (g/dL)</td>
<td rowspan="1" colspan="1">2.9 (2.6–3.2)</td>
<td rowspan="1" colspan="1">2.8 (2.6–3.2)</td>
<td rowspan="1" colspan="1">3.0 (2.8–3.3)</td>
<td rowspan="1" colspan="1">0.342</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Total bilirubin (mg/dL)</td>
<td rowspan="1" colspan="1">1.6 (0.9–3.2)</td>
<td rowspan="1" colspan="1">1.6 (0.80–2.48)</td>
<td rowspan="1" colspan="1">3.7 (1.5–8.4)</td>
<td rowspan="1" colspan="1">0.004</td>
</tr>
<tr>
<td rowspan="1" colspan="1">CRP (mg/dL)</td>
<td rowspan="1" colspan="1">5.8 (2.5–8.9)</td>
<td rowspan="1" colspan="1">5.7 (2.6–9.3)</td>
<td rowspan="1" colspan="1">6.6 (2.7–8.5)</td>
<td rowspan="1" colspan="1">0.951</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Immunosuppressed state<sup><a href="#tblfn5" class="usa-link">c</a></sup>
</td>
<td rowspan="1" colspan="1">46 (60.5)</td>
<td rowspan="1" colspan="1">32 (55.2)</td>
<td rowspan="1" colspan="1">14 (77.8)</td>
<td rowspan="1" colspan="1">0.104</td>
</tr>
<tr><td colspan="5" rowspan="1">Source of infection</td></tr>
<tr>
<td rowspan="1" colspan="1"> Hepatobiliary</td>
<td rowspan="1" colspan="1">32 (42.1)</td>
<td rowspan="1" colspan="1">27 (46.6)</td>
<td rowspan="1" colspan="1">5 (27.8)</td>
<td rowspan="6" colspan="1">0.571</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Intravascular catheter</td>
<td rowspan="1" colspan="1">14 (18.4)</td>
<td rowspan="1" colspan="1">9 (15.5)</td>
<td rowspan="1" colspan="1">5 (27.8)</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Febrile neutropenia</td>
<td rowspan="1" colspan="1">3 (3.9)</td>
<td rowspan="1" colspan="1">3 (5.2)</td>
<td rowspan="1" colspan="1">0 (0)</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Intra-abdominal</td>
<td rowspan="1" colspan="1">16 (21.1)</td>
<td rowspan="1" colspan="1">11 (19.0)</td>
<td rowspan="1" colspan="1">5 (27.8)</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Surgical site</td>
<td rowspan="1" colspan="1">9 (11.8)</td>
<td rowspan="1" colspan="1">6 (10.3)</td>
<td rowspan="1" colspan="1">3 (16.7)</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Others<sup><a href="#tblfn6" class="usa-link">d</a></sup>
</td>
<td rowspan="1" colspan="1">2 (2.6)</td>
<td rowspan="1" colspan="1">2 (3.4)</td>
<td rowspan="1" colspan="1">0 (0)</td>
</tr>
<tr><td colspan="5" rowspan="1">Concomitant antibiotics</td></tr>
<tr>
<td rowspan="1" colspan="1"> PIP/TZP</td>
<td rowspan="1" colspan="1">43 (56.6)</td>
<td rowspan="1" colspan="1">35 (60.3)</td>
<td rowspan="1" colspan="1">8 (44.4)</td>
<td rowspan="5" colspan="1">0.575</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> MEM</td>
<td rowspan="1" colspan="1">21 (27.6)</td>
<td rowspan="1" colspan="1">14 (24.1)</td>
<td rowspan="1" colspan="1">7 (38.9)</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> DOR</td>
<td rowspan="1" colspan="1">3 (3.9)</td>
<td rowspan="1" colspan="1">2 (3.4)</td>
<td rowspan="1" colspan="1">1 (5.6)</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> FEP</td>
<td rowspan="1" colspan="1">2 (2.6)</td>
<td rowspan="1" colspan="1">2 (3.4)</td>
<td rowspan="1" colspan="1">0 (0)</td>
</tr>
<tr>
<td rowspan="1" colspan="1"> Others<sup><a href="#tblfn7" class="usa-link">e</a></sup>
</td>
<td rowspan="1" colspan="1">7 (9.2)</td>
<td rowspan="1" colspan="1">5 (8.6)</td>
<td rowspan="1" colspan="1">2 (11.1)</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Polymicrobial infections</td>
<td rowspan="1" colspan="1">24 (31.6)</td>
<td rowspan="1" colspan="1">20 (34.5)</td>
<td rowspan="1" colspan="1">4 (22.2)</td>
<td rowspan="1" colspan="1">0.396</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Appropriateness of therapy</td>
<td rowspan="1" colspan="1">67 (88.2)</td>
<td rowspan="1" colspan="1">49 (84.5)</td>
<td rowspan="1" colspan="1">18 (100)</td>
<td rowspan="1" colspan="1">0.105</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Duration of therapy</td>
<td rowspan="1" colspan="1">19.5 (14.0–30.0)</td>
<td rowspan="1" colspan="1">17.0 (14.0–26.8)</td>
<td rowspan="1" colspan="1">29.5 (14.0–50.3)</td>
<td rowspan="1" colspan="1">0.055</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Source control<sup><a href="#tblfn8" class="usa-link">f</a></sup>
</td>
<td rowspan="1" colspan="1">62 (81.6)</td>
<td rowspan="1" colspan="1">47 (81.0)</td>
<td rowspan="1" colspan="1">15 (83.3)</td>
<td rowspan="1" colspan="1">1.000</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Length of hospital stay</td>
<td rowspan="1" colspan="1">60.5 (37.8–104.2)</td>
<td rowspan="1" colspan="1">51.0 (36.3–94.8)</td>
<td rowspan="1" colspan="1">109.5 (65.3–181.5)</td>
<td rowspan="1" colspan="1">0.010</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/dlaf151-T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tblfn1"><p>Data are presented as medians (IQRs) for continuous variables and <em>n</em> (%) for categorical variables unless otherwise stated.</p></div>
<div class="fn" id="tblfn2"><p>BMI, body mass index; BUN, blood urea nitrogen; COPD, chronic obstructive pulmonary disease; WBC, white blood cell; eGFR, estimated glomerular filtration rate; CRP, C-reactive protein; PIP/TZP, piperacillin/tazobactam; MEM, meropenem; DOR, doripenem; FEP, cefepime.</p></div>
<div class="fn" id="tblfn3"><p>
<sup>a</sup>Bacteraemia after 48 h of hospitalization.</p></div>
<div class="fn" id="tblfn4"><p>
<sup>b</sup>Neutropenia was defined as a neutrophil count of &lt;500/mm<sup>3</sup>.</p></div>
<div class="fn" id="tblfn5"><p>
<sup>c</sup>Use of chemotherapy and/or immunosuppressive drugs (corticosteroids, cyclosporin A/tacrolimus) within 1 month before bacteraemia.</p></div>
<div class="fn" id="tblfn6"><p>
<sup>d</sup>Respiratory (1) and urinary tract infection (1).</p></div>
<div class="fn" id="tblfn7"><p>
<sup>e</sup>Ciprofloxacin (1), cefmetazole (1), ceftriaxone (1), imipenem/cilastatin (1), minocycline plus ceftazidime (1), cefepime plus clindamycin (1) and no concomitant antibiotic (1).</p></div>
<div class="fn" id="tblfn8"><p>
<sup>f</sup>Incision, drainage and debridement (including endoscopic retrograde cholangiopancreatography, percutaneous transhepatic biliary drainage and removal of the central venous catheter).</p></div>
</div></section></section><section id="dlaf151-s3.2"><h3 class="pmc_sec_title">PK/PD analysis and target identification</h3>
<p>The primary outcome, treatment failure, occurred in 18 of 76 patients (23.7%). Follow-up blood cultures were obtained in 63 of 76 cases (83%). The overall 30-day mortality rate was 7.9% (6/76). To investigate the relationship between drug exposure and primary outcome, we first analysed the MIC distribution and then the teicoplanin PK/PD parameters. The MIC of each isolate was determined by Etest, as all MIC<sub>WalkAway</sub> values were ≤2 mg/L. The MIC<sub>Etest</sub> values for the 76 isolates ranged from 0.023 to 1 mg/L. The MIC<sub>Etest</sub> retests were performed on eight isolates according to the study protocol, and all retest results were within a 2-fold range of the initial values. As shown in Table <a href="#dlaf151-T2" class="usa-link">2</a>, there was a significant difference in the MIC<sub>Etest</sub> distribution between the treatment success and failure groups [median 0.25 mg/L (IQR, 0.13–0.50) versus 0.50 mg/L (IQR, 0.35–0.50); <em>P</em> = 0.008].</p>
<section class="tw xbox font-sm" id="dlaf151-T2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Teicoplanin PK/PD parameters</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">PK/PD parameters</th>
<th align="center" rowspan="1" colspan="1">Treatment success (<em>n</em> = 58)</th>
<th align="center" rowspan="1" colspan="1">Treatment failure (<em>n</em> = 18)</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em> value</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">MIC<sub>Etest</sub>
</td>
<td rowspan="1" colspan="1">0.25 (0.13–0.50)</td>
<td rowspan="1" colspan="1">0.50 (0.35–0.50)</td>
<td rowspan="1" colspan="1">0.008</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>C</em>
<sub>min</sub> (mg/L)</td>
<td rowspan="1" colspan="1">18.3 (15.0–23.1)</td>
<td rowspan="1" colspan="1">18.4 (9.70–23.1)</td>
<td rowspan="1" colspan="1">0.783</td>
</tr>
<tr>
<td rowspan="1" colspan="1">
<em>C</em>
<sub>min</sub>/MIC<sub>Etest</sub>
</td>
<td rowspan="1" colspan="1">72.1 (35.9–142.4)</td>
<td rowspan="1" colspan="1">42.0 (22.2–67.2)</td>
<td rowspan="1" colspan="1">0.013</td>
</tr>
<tr>
<td rowspan="1" colspan="1">fAUC<sub>24</sub> (mg·h/L)</td>
<td rowspan="1" colspan="1">96.9 (81.2–119.6)</td>
<td rowspan="1" colspan="1">96.9 (83.4–113.9)</td>
<td rowspan="1" colspan="1">0.869</td>
</tr>
<tr>
<td rowspan="1" colspan="1">fAUC<sub>24</sub>/MIC<sub>Etest</sub>
</td>
<td rowspan="1" colspan="1">412.3 (204.6–652.3)</td>
<td rowspan="1" colspan="1">245.3 (167.6–372.5)</td>
<td rowspan="1" colspan="1">0.021</td>
</tr>
<tr>
<td rowspan="1" colspan="1">fAUC<sub>24</sub>/MIC<sub>Etest</sub> ≥ 462</td>
<td rowspan="1" colspan="1">26 (44.8)</td>
<td rowspan="1" colspan="1">1 (5.6)</td>
<td rowspan="1" colspan="1">0.002</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/dlaf151-T2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tblfn9"><p>Data are presented as medians (IQRs) for continuous variables and <em>n</em> (%) for categorical variables unless otherwise stated.</p></div>
<div class="fn" id="tblfn10"><p>PK, pharmacokinetics; PD, pharmacodynamics; MIC, minimum inhibitory concentration; fAUC, free area under the curve.</p></div>
</div></section><p>Next, we compared several teicoplanin PK/PD parameters between the groups (Table <a href="#dlaf151-T2" class="usa-link">2</a>). The PK analysis for our 76 patients yielded substantial inter-individual variability (CV%) for clearance (39.2%) and steady-state volume of distribution (43.8%), while variability was low for the distribution rate parameters, α (4.7%) and K12 (0.1%). The median fAUC<sub>24</sub>/MIC<sub>Etest</sub> was found to be significantly higher in the treatment success group than in the treatment failure group [412.3 (IQR, 204.6–652.3) versus 245.3 (IQR, 167.6–372.5); <em>P</em> = 0.021]. In contrast, there were no significant differences in total <em>C</em><sub>min</sub> or fAUC<sub>24</sub> values alone. Based on this finding, we used CART analysis to determine the optimal fAUC<sub>24</sub>/MIC<sub>Etest</sub> cut-off value for predicting treatment failure, which was identified as 462. Figure <a href="#dlaf151-F2" class="usa-link">2</a> shows the distribution of treatment outcomes across different fAUC<sub>24</sub>/MIC<sub>Etest</sub> ranges. It demonstrates a marked reduction in treatment–failure ratio among patients with an fAUC<sub>24</sub>/MIC<sub>Etest</sub> ≥ 462.</p>
<figure class="fig xbox font-sm" id="dlaf151-F2"><h4 class="obj_head">Figure 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12368495_dlaf151f2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6158/12368495/192459e979d1/dlaf151f2.jpg" loading="lazy" height="390" width="750" alt="Figure 2."></a></p>
<div class="p text-right font-secondary"><a href="figure/dlaf151-F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Proportion of treatment failure according to fAUC<sub>24</sub>/MIC<sub>Etest</sub> values. The bar graph shows the number of patients with treatment success and treatment failure stratified by fAUC<sub>24</sub>/MIC<sub>Etest</sub> values. fAUC, free area under the curve.</p></figcaption></figure></section><section id="dlaf151-s3.3"><h3 class="pmc_sec_title">Clinical outcomes according to PK/PD target and toxicity analysis</h3>
<p>To evaluate the clinical relevance of this PK/PD target, we stratified patients by this cut-off and compared their outcomes (Table <a href="#dlaf151-T3" class="usa-link">3</a>). Patients who achieved the target (fAUC<sub>24</sub>/MIC<sub>Etest</sub> ≥ 462) had a significantly lower incidence of treatment failure compared to those who did not (3.7% versus 34.7%; <em>P</em> = 0.002).</p>
<section class="tw xbox font-sm" id="dlaf151-T3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Clinical outcomes according to PK/PD exposure</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
</colgroup>
<thead><tr>
<th align="left" rowspan="1" colspan="1">Outcomes</th>
<th align="center" rowspan="1" colspan="1">fAUC<sub>24</sub>/MIC<sub>Etest</sub> &lt; 462 (<em>n</em> = 49)</th>
<th align="center" rowspan="1" colspan="1">fAUC<sub>24</sub>/MIC<sub>Etest</sub> ≥ 462 (<em>n</em> = 27)</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em> value</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Treatment failure</td>
<td rowspan="1" colspan="1">17 (34.7)</td>
<td rowspan="1" colspan="1">1 (3.7)</td>
<td rowspan="1" colspan="1">0.002</td>
</tr>
<tr>
<td rowspan="1" colspan="1">30-day mortality</td>
<td rowspan="1" colspan="1">6 (12.2)</td>
<td rowspan="1" colspan="1">0 (0.0)</td>
<td rowspan="1" colspan="1">0.083</td>
</tr>
<tr>
<td rowspan="1" colspan="1">90-day mortality</td>
<td rowspan="1" colspan="1">17 (34.7)</td>
<td rowspan="1" colspan="1">3 (11.1)</td>
<td rowspan="1" colspan="1">0.031</td>
</tr>
<tr>
<td rowspan="1" colspan="1">In-hospital mortality</td>
<td rowspan="1" colspan="1">12 (24.5)</td>
<td rowspan="1" colspan="1">2 (7.4)</td>
<td rowspan="1" colspan="1">0.120</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Relapse</td>
<td rowspan="1" colspan="1">7 (14.3)</td>
<td rowspan="1" colspan="1">3 (11.1)</td>
<td rowspan="1" colspan="1">1.000</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Readmission within 90 days after bacteraemia</td>
<td rowspan="1" colspan="1">22 (44.9)</td>
<td rowspan="1" colspan="1">8 (29.6)</td>
<td rowspan="1" colspan="1">0.227</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/dlaf151-T3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="tblfn11"><p>Data are presented as <em>n</em> (%) for categorical variables.</p></div>
<div class="fn" id="tblfn12"><p>fAUC, free area under the curve; MIC, minimum inhibitory concentration; ADR, adverse drug reaction.</p></div>
</div></section><p>To explore the relationship between drug exposure and toxicity, fAUC<sub>24</sub> and <em>C</em><sub>min</sub> values were compared between patients with and without adverse events. There were no significant differences in median fAUC<sub>24</sub> or <em>C</em><sub>min</sub> values for patients who experienced nephrotoxicity (<em>n</em> = 6) compared to those who did not (fAUC<sub>24</sub>: 86.2 versus 99.4 mg·h/L, <em>P</em> = 0.184; <em>C</em><sub>min</sub>: 17.1 versus 18.4 mg/L, <em>P</em> = 0.470). Similarly, no significant association was found between drug exposure and the incidence of liver injury or other adverse drug reactions.</p></section><section id="dlaf151-s3.4"><h3 class="pmc_sec_title">Predictors of treatment failure</h3>
<p>The results of the multivariable logistic regression analysis are shown in Table <a href="#dlaf151-T4" class="usa-link">4</a>. After adjusting for the CCI, immunosuppressed state and Pitt bacteraemia score, achieving an fAUC<sub>24</sub>/MIC<sub>Etest</sub> ≥ 462 remained an independent predictor of reduced treatment failure (OR, 0.099; 95% CI, 0.005–0.562; <em>P</em> = 0.032). In this model, the other covariates were not significantly associated with the outcome.</p>
<section class="tw xbox font-sm" id="dlaf151-T4"><h4 class="obj_head">Table 4.</h4>
<div class="caption p"><p>Multivariable analysis of teicoplanin treatment failure</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2" colspan="1">Variables</th>
<th align="center" colspan="2" rowspan="1">Univariable</th>
<th align="center" colspan="2" rowspan="1">Multivariable</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1">Odds ratio (95% CI)</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em> value</th>
<th align="center" rowspan="1" colspan="1">Odds ratio (95% CI)</th>
<th align="center" rowspan="1" colspan="1">
<em>P</em> value</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">Teicoplanin fAUC<sub>24</sub>/MIC<sub>Etest</sub> ≥ 462</td>
<td rowspan="1" colspan="1">0.072 (0.004–0.389)</td>
<td rowspan="1" colspan="1">0.013</td>
<td rowspan="1" colspan="1">0.099 (0.005–0.562)</td>
<td rowspan="1" colspan="1">0.032</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Charlson Comorbidity Index</td>
<td rowspan="1" colspan="1">0.936 (0.744–1.142)</td>
<td rowspan="1" colspan="1">0.540</td>
<td rowspan="1" colspan="1">0.935 (0.709–1.184)</td>
<td rowspan="1" colspan="1">0.602</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Immunosuppressed state</td>
<td rowspan="1" colspan="1">2.844 (0.895–10.979)</td>
<td rowspan="1" colspan="1">0.095</td>
<td rowspan="1" colspan="1">2.603 (0.709–11.548)</td>
<td rowspan="1" colspan="1">0.170</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Pitt bacteraemia score</td>
<td rowspan="1" colspan="1">1.272 (1.019–1.611)</td>
<td rowspan="1" colspan="1">0.035</td>
<td rowspan="1" colspan="1">1.227 (0.975–1.580)</td>
<td rowspan="1" colspan="1">0.089</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/dlaf151-T4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="tblfn13"><p>fAUC, free area under the curve; MIC, minimum inhibitory concentration.</p></div></div></section><p>All variables in the final model had VIFs below 2, indicating no significant multicollinearity. Model calibration was assessed using the Hosmer–Lemeshow goodness-of-fit test, which indicated a good fit (<em>P</em> = 0.149). Discrimination, evaluated by the area under the receiver operating characteristic curve, was 0.792, indicating acceptable model performance.</p></section></section><section id="dlaf151-s4"><h2 class="pmc_sec_title">Discussion</h2>
<p>This study aimed to determine the teicoplanin PK/PD target associated with clinical outcomes in patients with GSEF bacteraemia. We found that a teicoplanin fAUC<sub>24</sub>/MIC<sub>Etest</sub> value of ≥462 was an independent predictor of reduced treatment failure, after adjusting for key clinical prognostic factors (Table <a href="#dlaf151-T4" class="usa-link">4</a>). To the best of our knowledge, this is the first study to identify a specific fAUC<sub>24</sub>/MIC<sub>Etest</sub> target for teicoplanin in this patient population.</p>
<p>Our analysis revealed that while total <em>C</em><sub>min</sub> and fAUC<sub>24</sub> values did not differ between the treatment success and failure groups, the PK/PD indices incorporating MIC, namely fAUC<sub>24</sub>/MIC<sub>Etest</sub> and <em>C</em><sub>min</sub>/MIC<sub>Etest</sub>, were significantly different (Table <a href="#dlaf151-T2" class="usa-link">2</a>). This underscores the critical role of MIC in determining therapeutic outcomes for GSEF bacteraemia. The median MIC<sub>Etest</sub> in the treatment failure group was double that of the success group (0.50 versus 0.25 mg/L), highlighting that even small variations in MIC can substantially impact the achievement of PK/PD targets. The MIC values in our cohort were relatively low compared to some reports from other regions,<sup><a href="#dlaf151-B36" class="usa-link" aria-describedby="dlaf151-B36">36</a></sup> suggesting that the PK/PD targets identified here may need to be validated in populations with different MIC distributions. Our previous report demonstrated that teicoplanin was non-inferior to vancomycin in efficacy, with a treatment success ratio of 64.9% in patients with GSEF bacteraemia; however, regions with different MIC distributions may yield different outcomes.<sup><a href="#dlaf151-B9" class="usa-link" aria-describedby="dlaf151-B9">9</a></sup> Studies comparing antimicrobial susceptibility testing methods for enterococci, including Etest, broth microdilution, disk diffusion and automated methods, have shown discrepancies in teicoplanin MIC values across methods.<sup><a href="#dlaf151-B37" class="usa-link" aria-describedby="dlaf151-B37">37</a>,<a href="#dlaf151-B38" class="usa-link" aria-describedby="dlaf151-B38">38</a></sup> Notably, these studies primarily focused on VRE, offering limited data applicable to GSEF. To ensure the reliability of MIC<sub>Etest</sub> values in this study, three clinical microbiologists were involved, with retesting conducted in cases of disagreement to minimize inter-operator variability. This approach enhances the reliability of the MIC<sub>Etest</sub> results. Future studies should further evaluate the reliability of teicoplanin MIC testing methods specifically for GSEF.</p>
<p>A key aspect of our study was the estimation of free drug concentrations. Teicoplanin is highly protein bound, and conditions such as hypoalbuminaemia, common in critically ill patients, can alter this binding. By calculating a patient-specific fu, we aimed to provide a more pharmacologically relevant assessment of drug exposure. While this estimation relies on a theoretical formula and a literature-derived fu, this approach is considered a valid alternative when direct measurement of free concentrations is not feasible.</p>
<p>The accuracy of AUC estimation itself, derived from a single trough concentration via a Bayesian approach, is another important consideration. In this study, we chose a two-compartment model by Nakayama et al., which is well-validated in Japanese patients. Although estimating distribution phase parameters from a single trough point has inherent limitations, our analysis of the individual parameters provided some reassurance. As shown in the <a href="#dlaf151-s3" class="usa-link">Results</a>, while the variability for distribution rate parameters was low, the substantial inter-individual variability for clearance (CV = 39.2%) and volume of distribution (<em>V</em><sub>dss</sub>, CV = 43.8%) suggests that the model robustly estimated these key parameters for each patient. Nevertheless, this single-point estimation method does not capture the impact of drug exposure during the critical initial phase of treatment and remains a limitation of our study. Future prospective studies with serial sampling during initial phase are warranted.</p>
<p>We discuss two perspectives on how to translate the findings of this study into clinical practice. First, we consider the importance of precise MIC determination. This study demonstrated the critical role of MIC values below the CLSI susceptibility breakpoint of 2 mg/L.<sup><a href="#dlaf151-B21" class="usa-link" aria-describedby="dlaf151-B21">21</a></sup> However, Etest is not routinely performed in many clinical settings. Our findings suggest that even small variations in MIC can substantially impact the achievement of PK/PD targets. Clinically, if a patient’s response is suboptimal despite adequate <em>C</em><sub>min</sub> levels, it is essential to consider the possibility of a higher-than-expected MIC. In such cases, confirming the precise MIC value with Etest and subsequently adjusting the dosage to increase fAUC or switching to an alternative agent may be necessary.</p>
<p>Second, we consider the utility of <em>C</em><sub>min</sub> as a surrogate marker. Since software for assessing fAUC is not widely available, <em>C</em><sub>min</sub> remains a practical alternative. In our study, the median <em>C</em><sub>min</sub> in both groups was approximately 18 mg/L, aligning with the recommended therapeutic range of 15–30 mg/L for MRSA.<sup><a href="#dlaf151-B22" class="usa-link" aria-describedby="dlaf151-B22">22</a>,<a href="#dlaf151-B39" class="usa-link" aria-describedby="dlaf151-B39">39</a></sup> Given that the majority of isolates in our cohort (84.2%) had an MIC ≤ 0.5 mg/L, a target <em>C</em><sub>min</sub> of 15–30 mg/L appears effective for treating most GSEF infections in regions with similar MIC distributions. This target <em>C</em><sub>min</sub> likely ensures that the fAUC<sub>24</sub>/MIC<sub>Etest</sub> target of ≥462 is achieved for these low-MIC isolates.</p>
<p>Regarding safety, our analysis showed no significant association between higher drug exposure (fAUC<sub>24</sub> or <em>C</em><sub>min</sub>) and the incidence of nephrotoxicity or other adverse events. This suggests that optimizing dosing to achieve the efficacy target of fAUC<sub>24</sub>/MIC<sub>Etest</sub> ≥ 462 is unlikely to increase the risk of toxicity, a finding consistent with previous meta-analyses on teicoplanin safety.<sup><a href="#dlaf151-B22" class="usa-link" aria-describedby="dlaf151-B22">22</a>,<a href="#dlaf151-B40" class="usa-link" aria-describedby="dlaf151-B40">40</a></sup></p>
<p>Despite the important clinical implications of this study, several limitations should be discussed. First, this was a retrospective analysis. While the multivariable analysis adjusted for patient backgrounds between the treatment success and treatment failure groups, unmeasured confounders that may have influenced treatment failure cannot be excluded. Known risk factors associated with clinical outcomes of teicoplanin therapy were systematically collected. Second, microbiological failure could not be assessed in all patients, which may have led to misclassification of the primary outcome. Third, this single-centre study was conducted at a university hospital, limiting the generalizability of the findings, particularly since over half of the participants were immunosuppressed. Fourth, the relatively small sample size, particularly the number of treatment failure cases, may have limited our ability to identify other significant predictors of the outcome.</p>
<p>Despite these limitations, this is the first study to identify a target fAUC<sub>24</sub>/MIC<sub>Etest</sub> value for teicoplanin in GSEF bacteraemia. The findings provide evidence supporting the importance of PK-/PD-based regimens in the treatment of GSEF bacteraemia.</p>
<p>In conclusion, this study demonstrated that a teicoplanin fAUC<sub>24</sub>/MIC<sub>Etest</sub> value of ≥462 was associated with reduced treatment failure in patients with GSEF bacteraemia, without increasing adverse drug events. Larger prospective studies are necessary to confirm these PK/PD targets for optimizing clinical outcomes and safety.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>During the preparation of this work, the authors used ChatGPT o3 (OpenAI) and Gemini 2.5 Pro (Google) solely to improve the readability and to proofread the English text. After utilizing these services, the authors reviewed and edited the content as necessary and assume full responsibility for the final manuscript.</p></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Ryo Yamaguchi, 
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.</p>
<p>Takehito Yamamoto, 
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.</p>
<p>Sohei Harada, 
Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.</p>
<p>Mayu Shibuya, 
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.</p>
<p>Miyuki Mizoguchi, 
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.</p>
<p>Yoshimi Higurashi, 
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.</p>
<p>Miho Echizenya, 
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.</p>
<p>Takeya Tsutsumi, 
Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan; 
Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.</p>
<p>Tappei Takada, 
Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.</p></section><section id="dlaf151-s5"><h2 class="pmc_sec_title">Funding</h2>
<p>This work was supported by the Japan Society for the Promotion of Science (JSPS) (grant number 23H05297).</p></section><section id="dlaf151-s6"><h2 class="pmc_sec_title">Transparency declarations</h2>
<p>S.H. reports speaker payments from MSD, Shionogi and Pfizer and consulting fees from Shionogi, Pfizer and Denka outside the submitted work. All other authors declare no conflict of interest.</p></section><section id="ref1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="dlaf151-B1">
<span class="label">1.</span><cite>

Arias  CA, Murray  BE. The rise of the <em>Enterococcus</em>: beyond vancomycin resistance. Nat Rev Microbiol  2012; 10: 266–78. 10.1038/nrmicro2761
</cite> [<a href="https://doi.org/10.1038/nrmicro2761" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3621121/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22421879/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Microbiol&amp;title=The%20rise%20of%20the%20Enterococcus:%20beyond%20vancomycin%20resistance&amp;volume=10&amp;publication_year=2012&amp;pages=266-78&amp;pmid=22421879&amp;doi=10.1038/nrmicro2761&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B2">
<span class="label">2.</span><cite>

Pinholt  M, Ostergaard  C, Arpi  M  et al.   Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006–2009: a population-based cohort study. Clin Microbiol Infect  2014; 20: 145–51. 10.1111/1469-0691.12236
</cite> [<a href="https://doi.org/10.1111/1469-0691.12236" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23647880/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Microbiol%20Infect&amp;title=Incidence,%20clinical%20characteristics%20and%2030-day%20mortality%20of%20enterococcal%20bacteraemia%20in%20Denmark%202006%E2%80%932009:%20a%20population-based%20cohort%20study&amp;volume=20&amp;publication_year=2014&amp;pages=145-51&amp;pmid=23647880&amp;doi=10.1111/1469-0691.12236&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B3">
<span class="label">3.</span><cite>

Cheah  AL, Spelman  T, Liew  D  et al.   Enterococcal bacteraemia: factors influencing mortality, length of stay and costs of hospitalization. Clin Microbiol Infect  2013; 19: E181–9. 10.1111/1469-0691.12132
</cite> [<a href="https://doi.org/10.1111/1469-0691.12132" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23398607/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Microbiol%20Infect&amp;title=Enterococcal%20bacteraemia:%20factors%20influencing%20mortality,%20length%20of%20stay%20and%20costs%20of%20hospitalization&amp;volume=19&amp;publication_year=2013&amp;pages=E181-9&amp;pmid=23398607&amp;doi=10.1111/1469-0691.12132&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B4">
<span class="label">4.</span><cite>

McBride  SJ, Upton  A, Roberts  SA. Clinical characteristics and outcomes of patients with vancomycin-susceptible <em>Enterococcus faecalis</em> and <em>Enterococcus faecium</em> bacteraemia–a five-year retrospective review. Eur J Clin Microbiol Infect Dis  2010; 29: 107–14. 10.1007/s10096-009-0830-5
</cite> [<a href="https://doi.org/10.1007/s10096-009-0830-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19916034/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Clin%20Microbiol%20Infect%20Dis&amp;title=Clinical%20characteristics%20and%20outcomes%20of%20patients%20with%20vancomycin-susceptible%20Enterococcus%20faecalis%20and%20Enterococcus%20faecium%20bacteraemia%E2%80%93a%20five-year%20retrospective%20review&amp;volume=29&amp;publication_year=2010&amp;pages=107-14&amp;pmid=19916034&amp;doi=10.1007/s10096-009-0830-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B5">
<span class="label">5.</span><cite>

de Kraker  ME, Jarlier  V, Monen  JC  et al.   The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. Clin Microbiol Infect  2013; 19: 860–8. 10.1111/1469-0691.12028
</cite> [<a href="https://doi.org/10.1111/1469-0691.12028" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23039210/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Microbiol%20Infect&amp;title=The%20changing%20epidemiology%20of%20bacteraemias%20in%20Europe:%20trends%20from%20the%20European%20Antimicrobial%20Resistance%20Surveillance%20System&amp;volume=19&amp;publication_year=2013&amp;pages=860-8&amp;pmid=23039210&amp;doi=10.1111/1469-0691.12028&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B6">
<span class="label">6.</span><cite>
European Centre for Disease Prevention and Control . Antimicrobial Resistance in the EU/EEA (EARS-Net)—Annual Epidemiological Report for 2022. ECDC, 2023. <a href="https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2022</a>.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Antimicrobial%20Resistance%20in%20the%20EU/EEA%20(EARS-Net)%E2%80%94Annual%20Epidemiological%20Report%20for%202022&amp;publication_year=2023&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B7">
<span class="label">7.</span><cite>
Ministry of Health, Labour and Welfare . Japan Nosocomial Infections Surveillance (JANIS). Open Report 2023 (Jan.-Dec. 2022) Clinical Laboratory Division. Published March 1, 2023. <a href="https://janis.mhlw.go.jp/english/report/open_report/2023/3/1/ken_Open_Report_Eng_202300_clsi2012.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://janis.mhlw.go.jp/english/report/open_report/2023/3/1/ken_Open_Report_Eng_202300_clsi2012.pdf</a>.</cite>
</li>
<li id="dlaf151-B8">
<span class="label">8.</span><cite>

Gorzynski  EA, Amsterdam  D, Beam  TR, Jr.  et al.   Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci. Antimicrob Agents Chemother  1989; 33: 2019–22. 10.1128/AAC.33.11.2019
</cite> [<a href="https://doi.org/10.1128/AAC.33.11.2019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC172808/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2532875/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrob%20Agents%20Chemother&amp;title=Comparative%20in%20vitro%20activities%20of%20teicoplanin,%20vancomycin,%20oxacillin,%20and%20other%20antimicrobial%20agents%20against%20bacteremic%20isolates%20of%20gram-positive%20cocci&amp;volume=33&amp;publication_year=1989&amp;pages=2019-22&amp;pmid=2532875&amp;doi=10.1128/AAC.33.11.2019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B9">
<span class="label">9.</span><cite>

Yamaguchi  R, Yamamoto  T, Okamoto  K  et al.   Teicoplanin and vancomycin as treatment for glycopeptide-susceptible <em>Enterococcus faecium</em> bacteraemia: a propensity score-adjusted non-inferior comparative study. J Antimicrob Chemother  2023; 78: 1231–40. 10.1093/jac/dkad079
</cite> [<a href="https://doi.org/10.1093/jac/dkad079" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10154127/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36918748/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Antimicrob%20Chemother&amp;title=Teicoplanin%20and%20vancomycin%20as%20treatment%20for%20glycopeptide-susceptible%20Enterococcus%20faecium%20bacteraemia:%20a%20propensity%20score-adjusted%20non-inferior%20comparative%20study&amp;volume=78&amp;publication_year=2023&amp;pages=1231-40&amp;pmid=36918748&amp;doi=10.1093/jac/dkad079&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B10">
<span class="label">10.</span><cite>

Watanabe  E, Matsumoto  K, Ikawa  K  et al.   Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against <em>Staphylococcus aureus</em> in a murine thigh infection model. J Glob Antimicrob Resist  2021; 24: 83–7. 10.1016/j.jgar.2020.11.014
</cite> [<a href="https://doi.org/10.1016/j.jgar.2020.11.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33290889/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Glob%20Antimicrob%20Resist&amp;title=Pharmacokinetic/pharmacodynamic%20evaluation%20of%20teicoplanin%20against%20Staphylococcus%20aureus%20in%20a%20murine%20thigh%20infection%20model&amp;volume=24&amp;publication_year=2021&amp;pages=83-7&amp;pmid=33290889&amp;doi=10.1016/j.jgar.2020.11.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B11">
<span class="label">11.</span><cite>

Craig  WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am  2003; 17: 479–501. 10.1016/S0891-5520(03)00065-5
</cite> [<a href="https://doi.org/10.1016/S0891-5520(03)00065-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14711073/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Infect%20Dis%20Clin%20North%20Am&amp;title=Basic%20pharmacodynamics%20of%20antibacterials%20with%20clinical%20applications%20to%20the%20use%20of%20beta-lactams,%20glycopeptides,%20and%20linezolid&amp;volume=17&amp;publication_year=2003&amp;pages=479-501&amp;pmid=14711073&amp;doi=10.1016/S0891-5520(03)00065-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B12">
<span class="label">12.</span><cite>

Byrne  CJ, Roberts  JA, McWhinney  B  et al.   Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy. Clin Microbiol Infect  2017; 23: 674.e7–e13. 10.1016/j.cmi.2017.02.032</cite> [<a href="https://doi.org/10.1016/j.cmi.2017.02.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28267636/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Microbiol%20Infect&amp;title=Population%20pharmacokinetics%20of%20teicoplanin%20and%20attainment%20of%20pharmacokinetic/pharmacodynamic%20targets%20in%20adult%20patients%20with%20haematological%20malignancy&amp;volume=23&amp;publication_year=2017&amp;pages=674.e7-e13&amp;pmid=28267636&amp;doi=10.1016/j.cmi.2017.02.032&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B13">
<span class="label">13.</span><cite>

Matsumoto  K, Watanabe  E, Kanazawa  N  et al.   Pharmacokinetic/pharmacodynamic analysis of teicoplanin in patients with MRSA infections. Clin Pharmacol  2016; 8: 15–8. 10.2147/CPAA.S96143
</cite> [<a href="https://doi.org/10.2147/CPAA.S96143" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4822798/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27099534/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol&amp;title=Pharmacokinetic/pharmacodynamic%20analysis%20of%20teicoplanin%20in%20patients%20with%20MRSA%20infections&amp;volume=8&amp;publication_year=2016&amp;pages=15-8&amp;pmid=27099534&amp;doi=10.2147/CPAA.S96143&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B14">
<span class="label">14.</span><cite>

Craig  WA. Does the dose matter?  Clin Infect Dis  2001; 33  Suppl 3: S233–7. 10.1086/321854
</cite> [<a href="https://doi.org/10.1086/321854" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11524724/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Does%20the%20dose%20matter?&amp;volume=33&amp;issue=Suppl%203&amp;publication_year=2001&amp;pages=S233-7&amp;pmid=11524724&amp;doi=10.1086/321854&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B15">
<span class="label">15.</span><cite>

Balli  EP, Venetis  CA, Miyakis  S. Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia. Antimicrob Agents Chemother  2014; 58: 734–9. 10.1128/AAC.01289-13
</cite> [<a href="https://doi.org/10.1128/AAC.01289-13" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3910884/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24247127/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrob%20Agents%20Chemother&amp;title=Systematic%20review%20and%20meta-analysis%20of%20linezolid%20versus%20daptomycin%20for%20treatment%20of%20vancomycin-resistant%20enterococcal%20bacteremia&amp;volume=58&amp;publication_year=2014&amp;pages=734-9&amp;pmid=24247127&amp;doi=10.1128/AAC.01289-13&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B16">
<span class="label">16.</span><cite>

Horan  TC, Andrus  M, Dudeck  MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control  2008; 36: 309–32. 10.1016/j.ajic.2008.03.002
</cite> [<a href="https://doi.org/10.1016/j.ajic.2008.03.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18538699/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Infect%20Control&amp;title=CDC/NHSN%20surveillance%20definition%20of%20health%20care-associated%20infection%20and%20criteria%20for%20specific%20types%20of%20infections%20in%20the%20acute%20care%20setting&amp;volume=36&amp;publication_year=2008&amp;pages=309-32&amp;pmid=18538699&amp;doi=10.1016/j.ajic.2008.03.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B17">
<span class="label">17.</span><cite>

Matsuo  S, Imai  E, Horio  M  et al.   Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis  2009; 53: 982–92. 10.1053/j.ajkd.2008.12.034
</cite> [<a href="https://doi.org/10.1053/j.ajkd.2008.12.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19339088/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Kidney%20Dis&amp;title=Revised%20equations%20for%20estimated%20GFR%20from%20serum%20creatinine%20in%20Japan&amp;volume=53&amp;publication_year=2009&amp;pages=982-92&amp;pmid=19339088&amp;doi=10.1053/j.ajkd.2008.12.034&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B18">
<span class="label">18.</span><cite>

Gudiol  C, Ayats  J, Camoez  M  et al.   Increase in bloodstream infection due to vancomycin-susceptible <em>Enterococcus faecium</em> in cancer patients: risk factors, molecular epidemiology and outcomes. PLoS One  2013; 8: e74734. 10.1371/journal.pone.0074734
</cite> [<a href="https://doi.org/10.1371/journal.pone.0074734" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3778008/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24069339/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Increase%20in%20bloodstream%20infection%20due%20to%20vancomycin-susceptible%20Enterococcus%20faecium%20in%20cancer%20patients:%20risk%20factors,%20molecular%20epidemiology%20and%20outcomes&amp;volume=8&amp;publication_year=2013&amp;pages=e74734&amp;pmid=24069339&amp;doi=10.1371/journal.pone.0074734&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B19">
<span class="label">19.</span><cite>

Echeverria-Esnal  D, Sorli  L, Prim  N  et al.   Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score matched comparative study. Int J Antimicrob Agents  2019; 54: 572–8. 10.1016/j.ijantimicag.2019.08.018
</cite> [<a href="https://doi.org/10.1016/j.ijantimicag.2019.08.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31476435/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Antimicrob%20Agents&amp;title=Linezolid%20vs%20glycopeptides%20in%20the%20treatment%20of%20glycopeptide-susceptible%20Enterococcus%20faecium%20bacteraemia:%20a%20propensity%20score%20matched%20comparative%20study&amp;volume=54&amp;publication_year=2019&amp;pages=572-8&amp;pmid=31476435&amp;doi=10.1016/j.ijantimicag.2019.08.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B20">
<span class="label">20.</span><cite>

Pena  C, Suarez  C, Ocampo-Sosa  A  et al.   Effect of adequate single-drug vs combination antimicrobial therapy on mortality in <em>Pseudomonas aeruginosa</em> bloodstream infections: a post hoc analysis of a prospective cohort. Clin Infect Dis  2013; 57: 208–16. 10.1093/cid/cit223
</cite> [<a href="https://doi.org/10.1093/cid/cit223" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23580739/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Effect%20of%20adequate%20single-drug%20vs%20combination%20antimicrobial%20therapy%20on%20mortality%20in%20Pseudomonas%20aeruginosa%20bloodstream%20infections:%20a%20post%20hoc%20analysis%20of%20a%20prospective%20cohort&amp;volume=57&amp;publication_year=2013&amp;pages=208-16&amp;pmid=23580739&amp;doi=10.1093/cid/cit223&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B21">
<span class="label">21.</span><cite>
Clinical and Laboratory Standards Institute . Performance Standards for Antimicrobial Susceptibility Testing—Twenty-Sixth Edition: M100. CLSI, 2016.</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Performance%20Standards%20for%20Antimicrobial%20Susceptibility%20Testing%E2%80%94Twenty-Sixth%20Edition:%20M100&amp;publication_year=2016&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B22">
<span class="label">22.</span><cite>

Hanai  Y, Takahashi  Y, Niwa  T  et al.   Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Antimicrob Chemother  2022; 77: 869–79. 10.1093/jac/dkab499
</cite> [<a href="https://doi.org/10.1093/jac/dkab499" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8969460/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35022752/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Antimicrob%20Chemother&amp;title=Clinical%20practice%20guidelines%20for%20therapeutic%20drug%20monitoring%20of%20teicoplanin:%20a%20consensus%20review%20by%20the%20Japanese%20Society%20of%20Chemotherapy%20and%20the%20Japanese%20Society%20of%20Therapeutic%20Drug%20Monitoring&amp;volume=77&amp;publication_year=2022&amp;pages=869-79&amp;pmid=35022752&amp;doi=10.1093/jac/dkab499&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B23">
<span class="label">23.</span><cite>

Nakayama  K, Gemma  H, Kaibara  A  et al.   Population pharmacokinetics of teicoplanin in adult patients [in Japanese]. Jpn J Chemother  2006; 54: 1–6. 10.11250/chemotherapy1995.54.1</cite> [<a href="https://doi.org/10.11250/chemotherapy1995.54.1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Jpn%20J%20Chemother&amp;title=Population%20pharmacokinetics%20of%20teicoplanin%20in%20adult%20patients%20%5Bin%20Japanese%5D&amp;volume=54&amp;publication_year=2006&amp;pages=1-6&amp;doi=10.11250/chemotherapy1995.54.1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B24">
<span class="label">24.</span><cite>

Kuti  JL, Kiffer  CR, Mendes  CM  et al.   Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of <em>Staphylococcus aureus</em> and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect  2008; 14: 116–23. 10.1111/j.1469-0691.2007.01885.x
</cite> [<a href="https://doi.org/10.1111/j.1469-0691.2007.01885.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18076672/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Microbiol%20Infect&amp;title=Pharmacodynamic%20comparison%20of%20linezolid,%20teicoplanin%20and%20vancomycin%20against%20clinical%20isolates%20of%20Staphylococcus%20aureus%20and%20coagulase-negative%20staphylococci%20collected%20from%20hospitals%20in%20Brazil&amp;volume=14&amp;publication_year=2008&amp;pages=116-23&amp;pmid=18076672&amp;doi=10.1111/j.1469-0691.2007.01885.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B25">
<span class="label">25.</span><cite>

Yano  R, Nakamura  T, Tsukamoto  H  et al.   Variability in teicoplanin protein binding and its prediction using serum albumin concentrations. Ther Drug Monit  2007; 29: 399–403. 10.1097/FTD.0b013e3180690755
</cite> [<a href="https://doi.org/10.1097/FTD.0b013e3180690755" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17667792/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ther%20Drug%20Monit&amp;title=Variability%20in%20teicoplanin%20protein%20binding%20and%20its%20prediction%20using%20serum%20albumin%20concentrations&amp;volume=29&amp;publication_year=2007&amp;pages=399-403&amp;pmid=17667792&amp;doi=10.1097/FTD.0b013e3180690755&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B26">
<span class="label">26.</span><cite>

Sonoda  A, Iwashita  Y, Takada  Y  et al.   Prediction accuracy of area under the concentration-time curve of vancomycin by Bayesian approach using creatinine-based equations of estimated kidney function in bedridden elderly Japanese patients. Biol Pharm Bull  2022; 45: 763–9. 10.1248/bpb.b22-00070
</cite> [<a href="https://doi.org/10.1248/bpb.b22-00070" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35370223/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biol%20Pharm%20Bull&amp;title=Prediction%20accuracy%20of%20area%20under%20the%20concentration-time%20curve%20of%20vancomycin%20by%20Bayesian%20approach%20using%20creatinine-based%20equations%20of%20estimated%20kidney%20function%20in%20bedridden%20elderly%20Japanese%20patients&amp;volume=45&amp;publication_year=2022&amp;pages=763-9&amp;pmid=35370223&amp;doi=10.1248/bpb.b22-00070&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B27">
<span class="label">27.</span><cite>

Oda  K. Development of software for antimicrobial PK/PD simulation incorporating Monte Carlo simulation based on Microsoft<sup>®</sup> Office Excel [in Japanese]. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)  2011; 37: 335–44. 10.5649/jjphcs.37.335</cite> [<a href="https://doi.org/10.5649/jjphcs.37.335" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Iryo%20Yakugaku%20(Japanese%20Journal%20of%20Pharmaceutical%20Health%20Care%20and%20Sciences)&amp;title=Development%20of%20software%20for%20antimicrobial%20PK/PD%20simulation%20incorporating%20Monte%20Carlo%20simulation%20based%20on%20Microsoft%C2%AE%20Office%20Excel%20%5Bin%20Japanese%5D&amp;volume=37&amp;publication_year=2011&amp;pages=335-44&amp;doi=10.5649/jjphcs.37.335&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B28">
<span class="label">28.</span><cite>

Song  KH, Kim  HB, Kim  HS  et al.   Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant <em>Staphylococcus aureus</em> bacteraemia. Int J Antimicrob Agents  2015; 46: 689–95. 10.1016/j.ijantimicag.2015.09.010
</cite> [<a href="https://doi.org/10.1016/j.ijantimicag.2015.09.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26555059/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Antimicrob%20Agents&amp;title=Impact%20of%20area%20under%20the%20concentration-time%20curve%20to%20minimum%20inhibitory%20concentration%20ratio%20on%20vancomycin%20treatment%20outcomes%20in%20methicillin-resistant%20Staphylococcus%20aureus%20bacteraemia&amp;volume=46&amp;publication_year=2015&amp;pages=689-95&amp;pmid=26555059&amp;doi=10.1016/j.ijantimicag.2015.09.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B29">
<span class="label">29.</span><cite>

Britt  NS, Potter  EM, Patel  N  et al.   Comparison of the effectiveness and safety of linezolid and daptomycin in vancomycin-resistant enterococcal bloodstream infection: a national cohort study of veterans affairs patients. Clin Infect Dis  2015; 61: 871–8. 10.1093/cid/civ444
</cite> [<a href="https://doi.org/10.1093/cid/civ444" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4551009/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26063715/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Infect%20Dis&amp;title=Comparison%20of%20the%20effectiveness%20and%20safety%20of%20linezolid%20and%20daptomycin%20in%20vancomycin-resistant%20enterococcal%20bloodstream%20infection:%20a%20national%20cohort%20study%20of%20veterans%20affairs%20patients&amp;volume=61&amp;publication_year=2015&amp;pages=871-8&amp;pmid=26063715&amp;doi=10.1093/cid/civ444&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B30">
<span class="label">30.</span><cite>
Kidney Disease: Improving Global Outcomes (KDIGO), Acute Kidney Injury Work Group . KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl  2012; 2: 1–138. 10.1038/kisup.2012.1</cite> [<a href="https://doi.org/10.1038/kisup.2012.1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int%20Suppl&amp;title=KDIGO%20clinical%20practice%20guideline%20for%20acute%20kidney%20injury&amp;volume=2&amp;publication_year=2012&amp;pages=1-138&amp;doi=10.1038/kisup.2012.1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B31">
<span class="label">31.</span><cite>

Senior  JR. Monitoring for hepatotoxicity: what is the predictive value of liver “function” tests?  Clin Pharmacol Ther  2009; 85: 331–4. 10.1038/clpt.2008.262
</cite> [<a href="https://doi.org/10.1038/clpt.2008.262" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19129750/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&amp;title=Monitoring%20for%20hepatotoxicity:%20what%20is%20the%20predictive%20value%20of%20liver%20%E2%80%9Cfunction%E2%80%9D%20tests?&amp;volume=85&amp;publication_year=2009&amp;pages=331-4&amp;pmid=19129750&amp;doi=10.1038/clpt.2008.262&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B32">
<span class="label">32.</span><cite>

Jumah  MTB, Vasoo  S, Menon  SR  et al.   Pharmacokinetic/pharmacodynamic determinants of vancomycin efficacy in enterococcal bacteremia. Antimicrob Agents Chemother  2018; 62: e01602–17. 10.1128/AAC.01602-17
</cite> [<a href="https://doi.org/10.1128/AAC.01602-17" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5826144/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29263057/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrob%20Agents%20Chemother&amp;title=Pharmacokinetic/pharmacodynamic%20determinants%20of%20vancomycin%20efficacy%20in%20enterococcal%20bacteremia&amp;volume=62&amp;publication_year=2018&amp;pages=e01602-17&amp;pmid=29263057&amp;doi=10.1128/AAC.01602-17&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B33">
<span class="label">33.</span><cite>

Rothe  K, Bachfischer  T, Karapetyan  S  et al.   Are enterococcal bloodstream infections an independent risk factor for a poorer 5-year survival or just a marker for severity of illness? The Munich multicentric enterococci cohort. Microbiol Spectr  2023; 11: e0258523. 10.1128/spectrum.02585-23
</cite> [<a href="https://doi.org/10.1128/spectrum.02585-23" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10715215/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37791770/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Microbiol%20Spectr&amp;title=Are%20enterococcal%20bloodstream%20infections%20an%20independent%20risk%20factor%20for%20a%20poorer%205-year%20survival%20or%20just%20a%20marker%20for%20severity%20of%20illness?%20The%20Munich%20multicentric%20enterococci%20cohort&amp;volume=11&amp;publication_year=2023&amp;pages=e0258523&amp;pmid=37791770&amp;doi=10.1128/spectrum.02585-23&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B34">
<span class="label">34.</span><cite>

Billington  EO, Phang  SH, Gregson  DB  et al.   Incidence, risk factors, and outcomes for <em>Enterococcus</em> spp. blood stream infections: a population-based study. Int J Infect Dis  2014; 26: 76–82. 10.1016/j.ijid.2014.02.012
</cite> [<a href="https://doi.org/10.1016/j.ijid.2014.02.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24813873/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Infect%20Dis&amp;title=Incidence,%20risk%20factors,%20and%20outcomes%20for%20Enterococcus%20spp.%20blood%20stream%20infections:%20a%20population-based%20study&amp;volume=26&amp;publication_year=2014&amp;pages=76-82&amp;pmid=24813873&amp;doi=10.1016/j.ijid.2014.02.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B35">
<span class="label">35.</span><cite>

Rinaldi  M, Rancan  I, Malerba  F  et al.   <em>Enterococcus faecium</em> bacteraemia: a multicentre observational study focused on risk factors for clinical and microbiological outcomes. J Antimicrob Chemother  2025: 80: 2247–56. 10.1093/jac/dkaf197
</cite> [<a href="https://doi.org/10.1093/jac/dkaf197" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12313462/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40577612/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Antimicrob%20Chemother&amp;title=Enterococcus%20faecium%20bacteraemia:%20a%20multicentre%20observational%20study%20focused%20on%20risk%20factors%20for%20clinical%20and%20microbiological%20outcomes&amp;volume=80&amp;publication_year=2025&amp;pages=2247-56&amp;pmid=40577612&amp;doi=10.1093/jac/dkaf197&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B36">
<span class="label">36.</span><cite>

Hällgren  A, Abednazari  H, Ekdahl  C  et al.   Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems. J Antimicrob Chemother  2001; 48: 53–62. 10.1093/jac/48.1.53
</cite> [<a href="https://doi.org/10.1093/jac/48.1.53" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11418512/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Antimicrob%20Chemother&amp;title=Antimicrobial%20susceptibility%20patterns%20of%20enterococci%20in%20intensive%20care%20units%20in%20Sweden%20evaluated%20by%20different%20MIC%20breakpoint%20systems&amp;volume=48&amp;publication_year=2001&amp;pages=53-62&amp;pmid=11418512&amp;doi=10.1093/jac/48.1.53&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B37">
<span class="label">37.</span><cite>

Cormican  MG, Biedenbach  D, Jones  RN. Reevaluation of contemporary laboratory methods for detection of antimicrobial resistance among enterococci. Clin Microbiol Infect  1996; 1: 190–4. 10.1111/j.1469-0691.1996.tb00552.x
</cite> [<a href="https://doi.org/10.1111/j.1469-0691.1996.tb00552.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11866756/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Microbiol%20Infect&amp;title=Reevaluation%20of%20contemporary%20laboratory%20methods%20for%20detection%20of%20antimicrobial%20resistance%20among%20enterococci&amp;volume=1&amp;publication_year=1996&amp;pages=190-4&amp;pmid=11866756&amp;doi=10.1111/j.1469-0691.1996.tb00552.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B38">
<span class="label">38.</span><cite>

Raponi  G, Ghezzi  MC, Gherardi  G  et al.   Analysis of methods commonly used for glycopeptide and oxazolidinone susceptibility testing in <em>Enterococcus faecium</em> isolates. J Med Microbiol  2010; 59: 672–8. 10.1099/jmm.0.016444-0
</cite> [<a href="https://doi.org/10.1099/jmm.0.016444-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20185550/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Med%20Microbiol&amp;title=Analysis%20of%20methods%20commonly%20used%20for%20glycopeptide%20and%20oxazolidinone%20susceptibility%20testing%20in%20Enterococcus%20faecium%20isolates&amp;volume=59&amp;publication_year=2010&amp;pages=672-8&amp;pmid=20185550&amp;doi=10.1099/jmm.0.016444-0&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B39">
<span class="label">39.</span><cite>

Hanai  Y, Takahashi  Y, Niwa  T  et al.   Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant <em>Staphylococcus aureus</em> infection: a systematic review and meta-analysis. J Clin Pharm Ther  2021; 46: 622–32. 10.1111/jcpt.13366
</cite> [<a href="https://doi.org/10.1111/jcpt.13366" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33547647/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Pharm%20Ther&amp;title=Optimal%20trough%20concentration%20of%20teicoplanin%20for%20the%20treatment%20of%20methicillin-resistant%20Staphylococcus%20aureus%20infection:%20a%20systematic%20review%20and%20meta-analysis&amp;volume=46&amp;publication_year=2021&amp;pages=622-32&amp;pmid=33547647&amp;doi=10.1111/jcpt.13366&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="dlaf151-B40">
<span class="label">40.</span><cite>

Davey  PG, Williams  AH. Teicoplanin monotherapy of serious infections caused by gram-positive bacteria: a re-evaluation of patients with endocarditis or <em>Staphylococcus aureus</em> bacteraemia from a European open trial. J Antimicrob Chemother  1991; 27  Suppl B: 43–50. 10.1093/jac/27.suppl_B.43</cite> [<a href="https://doi.org/10.1093/jac/27.suppl_B.43" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1829076/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Antimicrob%20Chemother&amp;title=Teicoplanin%20monotherapy%20of%20serious%20infections%20caused%20by%20gram-positive%20bacteria:%20a%20re-evaluation%20of%20patients%20with%20endocarditis%20or%20Staphylococcus%20aureus%20bacteraemia%20from%20a%20European%20open%20trial&amp;volume=27&amp;issue=Suppl%20B&amp;publication_year=1991&amp;pages=43-50&amp;pmid=1829076&amp;doi=10.1093/jac/27.suppl_B.43&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from JAC-Antimicrobial Resistance are provided here courtesy of <strong>British Society for Antimicrobial Chemotherapy and Oxford University Press</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1093/jacamr/dlaf151"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/dlaf151.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (308.8 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12368495/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12368495/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12368495%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12368495/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12368495/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12368495/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40851898/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12368495/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40851898/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12368495/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12368495/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="J8NnoLhEmXW0wtrGx9ihTdbmZPVVyfi7sUCO9tHnGxpMqsaKj7j1ybPSDPdbtWYC">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
        <script type="module" crossorigin="" src="/static/assets/math-574fdcc6.js"></script>
    
    

    </body>
</html>
